Chimeric West Nile/dengue virus vaccine candidate: preclinical evaluation in mice, geese and monkeys for safety and immunogenicity.

Toll-like receptor 7-induced immune response to cutaneous West Nile virus infection. J Gen Virol (2009) 1.22

An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody. J Virol (2013) 1.14

Drak2 contributes to West Nile virus entry into the brain and lethal encephalitis. J Immunol (2008) 1.13

Recent progress in West Nile virus diagnosis and vaccination. Vet Res (2012) 1.09

The neurovirulence and neuroinvasiveness of chimeric tick-borne encephalitis/dengue virus can be attenuated by introducing defined mutations into the envelope and NS5 protein genes and the 3' non-coding region of the genome. Virology (2010) 1.05

MicroRNA targeting of neurotropic flavivirus: effective control of virus escape and reversion to neurovirulent phenotype. J Virol (2012) 1.05

Comparative neuropathogenesis and neurovirulence of attenuated flaviviruses in nonhuman primates. J Virol (2008) 1.01

gammadelta T cells promote the maturation of dendritic cells during West Nile virus infection. FEMS Immunol Med Microbiol (2010) 1.00

A chimeric dengue virus vaccine using Japanese encephalitis virus vaccine strain SA14-14-2 as backbone is immunogenic and protective against either parental virus in mice and nonhuman primates. J Virol (2013) 0.94

Current trends in West Nile virus vaccine development. Expert Rev Vaccines (2014) 0.93

Identification of mutated cyclization sequences that permit efficient replication of West Nile virus genomes: use in safer propagation of a novel vaccine candidate. J Virol (2008) 0.92

Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1. Virol J (2007) 0.91

Vaccines in development against West Nile virus. Viruses (2013) 0.90

The live attenuated chimeric vaccine rWN/DEN4Δ30 is well-tolerated and immunogenic in healthy flavivirus-naïve adult volunteers. Vaccine (2013) 0.89

Evaluation of RepliVAX WN, a single-cycle flavivirus vaccine, in a non-human primate model of West Nile virus infection. Am J Trop Med Hyg (2010) 0.88

Microarray hybridization for assessment of the genetic stability of chimeric West Nile/dengue 4 virus. J Med Virol (2011) 0.85

Targeted mutagenesis as a rational approach to dengue virus vaccine development. Curr Top Microbiol Immunol (2010) 0.83

Evaluation of St. Louis encephalitis virus/dengue virus type 4 antigenic chimeric viruses in mice and rhesus monkeys. Vaccine (2008) 0.83

A review of vaccine approaches for West Nile virus. Int J Environ Res Public Health (2013) 0.83

Silencing of neurotropic flavivirus replication in the central nervous system by combining multiple microRNA target insertions in two distinct viral genome regions. Virology (2014) 0.82

Immunogenicity of RepliVAX WN, a novel single-cycle West Nile virus vaccine. Vaccine (2010) 0.82

Cellular inflammatory response to flaviviruses in the central nervous system of a primate host. J Histochem Cytochem (2009) 0.82

A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF+ cells. Vaccine (2008) 0.82

Assurance of neuroattenuation of a live vaccine against West Nile virus: a comprehensive study of neuropathogenesis after infection with chimeric WN/DEN4Δ30 vaccine in comparison to two parental viruses and a surrogate flavivirus reference vaccine. Vaccine (2014) 0.81

MicroRNA-based control of tick-borne flavivirus neuropathogenesis: Challenges and perspectives. Antiviral Res (2016) 0.80

Neuropathogenesis and neurovirulence of live flaviviral vaccines in monkeys. J Virol (2009) 0.78

Evaluation of the efficacy of a recombinant subunit West Nile vaccine in Syrian golden hamsters. Am J Trop Med Hyg (2008) 0.77

Plant-made vaccines against West Nile virus are potent, safe, and economically feasible. Biotechnol J (2015) 0.76

Role of γδ T cells in West Nile virus-induced encephalitis: friend or foe? J Neuroimmunol (2011) 0.76

A recombinant chimeric La Crosse virus expressing the surface glycoproteins of Jamestown Canyon virus is immunogenic and protective against challenge with either parental virus in mice or monkeys. J Virol (2011) 0.76

A hamster-derived West Nile virus strain is highly attenuated and induces a differential proinflammatory cytokine response in two murine cell lines. Virus Res (2012) 0.76

Vaccine-induced protection of rhesus macaques against plasma viremia after intradermal infection with a European lineage 1 strain of West Nile virus. PLoS One (2014) 0.75

A Live Attenuated Chimeric West Nile Virus Vaccine, rWN/DEN4Δ30, Is Well Tolerated and Immunogenic in Flavivirus-Naive Older Adult Volunteers. J Infect Dis (2016) 0.75

Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science (2005) 17.19

A two-amino acid change in the hemagglutinin of the 1918 influenza virus abolishes transmission. Science (2007) 8.38

Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus. Nature (2006) 6.46

Prospects for a dengue virus vaccine. Nat Rev Microbiol (2007) 4.99

An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med (2004) 4.89

Pathogenicity of influenza viruses with genes from the 1918 pandemic virus: functional roles of alveolar macrophages and neutrophils in limiting virus replication and mortality in mice. J Virol (2005) 4.72

The evolutionary genetics and emergence of avian influenza viruses in wild birds. PLoS Pathog (2008) 4.17

Pathogenicity and immunogenicity of influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci U S A (2004) 4.00

A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature (2004) 3.90

Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis (2005) 3.79

Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med (2006) 3.71

Susceptibility of North American ducks and gulls to H5N1 highly pathogenic avian influenza viruses. Emerg Infect Dis (2006) 3.36

Persistence of H5 and H7 avian influenza viruses in water. Avian Dis (2007) 3.17

Characterization of highly pathogenic H5N1 avian influenza A viruses isolated from South Korea. J Virol (2005) 2.97

Global host immune response: pathogenesis and transcriptional profiling of type A influenza viruses expressing the hemagglutinin and neuraminidase genes from the 1918 pandemic virus. J Virol (2004) 2.67

Genetic diversity between human metapneumovirus subgroups. Virology (2003) 2.65

A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial. J Infect Dis (2013) 2.51

Isolation and characterization of avian influenza viruses, including highly pathogenic H5N1, from poultry in live bird markets in Hanoi, Vietnam, in 2001. J Virol (2005) 2.51

Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J Virol (2006) 2.47

Phylogenetic diversity among low-virulence newcastle disease viruses from waterfowl and shorebirds and comparison of genotype distributions to those of poultry-origin isolates. J Virol (2007) 2.47

rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J Infect Dis (2005) 2.46

Development of effective vaccines against pandemic influenza. Immunity (2006) 2.45

Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet (2004) 2.43

Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci U S A (2004) 2.38

Pathogenicity of a Hong Kong-origin H5N1 highly pathogenic avian influenza virus for emus, geese, ducks, and pigeons. Avian Dis (2002) 2.38

Neuraminidase stalk length and additional glycosylation of the hemagglutinin influence the virulence of influenza H5N1 viruses for mice. J Virol (2009) 2.32

Pause on avian flu transmission research. Science (2012) 2.24

Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci U S A (2002) 2.21

Evidence for a new avian paramyxovirus serotype 10 detected in rockhopper penguins from the Falkland Islands. J Virol (2010) 2.21

Experimental infection of swans and geese with highly pathogenic avian influenza virus (H5N1) of Asian lineage. Emerg Infect Dis (2008) 2.12

Phylogenetic analyses of type A influenza genes in natural reservoir species in North America reveals genetic variation. Virus Res (2005) 2.06

Successful topical respiratory tract immunization of primates against Ebola virus. J Virol (2007) 2.06

Recombinant human Metapneumovirus lacking the small hydrophobic SH and/or attachment G glycoprotein: deletion of G yields a promising vaccine candidate. J Virol (2004) 2.03

The two major human metapneumovirus genetic lineages are highly related antigenically, and the fusion (F) protein is a major contributor to this antigenic relatedness. J Virol (2004) 2.02

Characterization of a highly pathogenic H5N1 avian influenza A virus isolated from duck meat. J Virol (2002) 1.85

Public health risk from avian influenza viruses. Avian Dis (2005) 1.84

Recovery of human metapneumovirus from cDNA: optimization of growth in vitro and expression of additional genes. Virology (2004) 1.81

Pathogenesis of pandemic influenza A (H1N1) and triple-reassortant swine influenza A (H1) viruses in mice. J Virol (2010) 1.79

Movements of birds and avian influenza from Asia into Alaska. Emerg Infect Dis (2007) 1.78

Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates. J Virol (2005) 1.72

Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci U S A (2004) 1.69

The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine (2007) 1.68

Domestic pigs have low susceptibility to H5N1 highly pathogenic avian influenza viruses. PLoS Pathog (2008) 1.66

West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy. Proc Natl Acad Sci U S A (2002) 1.65

Comparative susceptibility of chickens and turkeys to avian influenza A H7N2 virus infection and protective efficacy of a commercial avian influenza H7N2 virus vaccine. Avian Dis (2004) 1.62

Infection of nonhuman primates with recombinant human metapneumovirus lacking the SH, G, or M2-2 protein categorizes each as a nonessential accessory protein and identifies vaccine candidates. J Virol (2005) 1.59

New generation live vaccines against human respiratory syncytial virus designed by reverse genetics. Proc Am Thorac Soc (2005) 1.58

Susceptibility of laughing gulls (Larus atricilla) to H5N1 and H5N3 highly pathogenic avian influenza viruses. Avian Dis (2002) 1.58

A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge. J Virol (2006) 1.58

Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J Virol (2005) 1.56

A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults. Vaccine (2009) 1.56

Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells. Virology (2002) 1.55

Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus. J Virol (2007) 1.55

Nonsegmented negative-strand viruses as vaccine vectors. J Virol (2006) 1.53

A trade-off in replication in mosquito versus mammalian systems conferred by a point mutation in the NS4B protein of dengue virus type 4. Virology (2003) 1.51

Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults. Vaccine (2009) 1.51

Respiratory syncytial virus: reverse genetics and vaccine strategies. Virology (2002) 1.51

A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3' untranslated region is highly attenuated and immunogenic in monkeys. J Virol (2003) 1.50

A combination in-ovo vaccine for avian influenza virus and Newcastle disease virus. Vaccine (2007) 1.48

Influenza-A viruses in ducks in northwestern Minnesota: fine scale spatial and temporal variation in prevalence and subtype diversity. PLoS One (2011) 1.47

Development of a live attenuated dengue virus vaccine using reverse genetics. Viral Immunol (2006) 1.44

A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults. J Infect Dis (2009) 1.40

Lethal dissemination of H5N1 influenza virus is associated with dysregulation of inflammation and lipoxin signaling in a mouse model of infection. J Virol (2010) 1.40

Susceptibility of wood ducks to H5N1 highly pathogenic avian influenza virus. J Wildl Dis (2007) 1.39

Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens. Proc Natl Acad Sci U S A (2007) 1.39

Ferrets develop fatal influenza after inhaling small particle aerosols of highly pathogenic avian influenza virus A/Vietnam/1203/2004 (H5N1). Virol J (2010) 1.36

rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults. Hum Vaccin (2006) 1.36

Role of poultry in the spread of novel H7N9 influenza virus in China. J Virol (2014) 1.36

The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers. Hum Vaccin (2006) 1.35

Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2. BMC Infect Dis (2004) 1.35

Pathobiology of Asian highly pathogenic avian influenza H5N1 virus infections in ducks. Avian Dis (2007) 1.35

Avian influenza viruses and paramyxoviruses in wintering and resident ducks in Texas. J Wildl Dis (2005) 1.35

Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone. J Virol (2002) 1.34

Pathogenesis of 1918 pandemic and H5N1 influenza virus infections in a guinea pig model: antiviral potential of exogenous alpha interferon to reduce virus shedding. J Virol (2009) 1.32

Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys. J Virol (2009) 1.32

Paired charge-to-alanine mutagenesis of dengue virus type 4 NS5 generates mutants with temperature-sensitive, host range, and mouse attenuation phenotypes. J Virol (2002) 1.32

A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants. Pediatr Infect Dis J (2003) 1.32

Deletion of M2 gene open reading frames 1 and 2 of human metapneumovirus: effects on RNA synthesis, attenuation, and immunogenicity. J Virol (2005) 1.32

The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans. J Infect Dis (2006) 1.30

Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity. Am J Trop Med Hyg (2008) 1.28

Development and evaluation of an Influenza virus subtype H7N2 vaccine candidate for pandemic preparedness. Clin Vaccine Immunol (2007) 1.27

H5N2 avian influenza outbreak in Texas in 2004: the first highly pathogenic strain in the United States in 20 years? J Virol (2005) 1.26

Novel Reassortant Clade 2.3.4.4 Avian Influenza A(H5N8) Virus in Wild Aquatic Birds, Russia, 2016. Emerg Infect Dis (2017) 1.26

Pathogenesis of H5N1 influenza virus infections in mice and ferret models differs according to respiratory tract or digestive system exposure. J Infect Dis (2009) 1.26

The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes. J Virol (2008) 1.25

Sequence analysis of the Washington/1964 strain of human parainfluenza virus type 1 (HPIV1) and recovery and characterization of wild-type recombinant HPIV1 produced by reverse genetics. Virus Genes (2002) 1.25

Amelioration of influenza virus pathogenesis in chickens attributed to the enhanced interferon-inducing capacity of a virus with a truncated NS1 gene. J Virol (2006) 1.24

Early control of H5N1 influenza virus replication by the type I interferon response in mice. J Virol (2009) 1.24

Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys. Vaccine (2003) 1.24

Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine candidate in Vero cells. Vaccine (2003) 1.24

Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge. Virology (2008) 1.21

Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response. Vaccine (2010) 1.20

Highly Pathogenic Avian Influenza Viruses and Generation of Novel Reassortants, United States, 2014-2015. Emerg Infect Dis (2016) 1.20

Introduction of mutations into the non-structural genes or 3' untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity. Vaccine (2004) 1.19

The genome length of human parainfluenza virus type 2 follows the rule of six, and recombinant viruses recovered from non-polyhexameric-length antigenomic cDNAs contain a biased distribution of correcting mutations. J Virol (2003) 1.19

Genetically modified, live attenuated dengue virus type 3 vaccine candidates. Am J Trop Med Hyg (2004) 1.19

Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus. Virology (2003) 1.19

Comparative pathobiology of low and high pathogenicity H7N3 Chilean avian influenza viruses in chickens. Avian Dis (2004) 1.19

Role of interferon in the replication of human parainfluenza virus type 1 wild type and mutant viruses in human ciliated airway epithelium. J Virol (2008) 1.18